News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
718,327 Results
Type
Article (42482)
Company Profile (294)
Press Release (675551)
Multimedia
Podcasts (79)
Webinars (12)
Section
Business (210448)
Career Advice (2091)
Deals (36630)
Drug Delivery (107)
Drug Development (83055)
Employer Resources (175)
FDA (16575)
Job Trends (15409)
News (356057)
Policy (33921)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (5)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2598)
Accelerated approval (5)
Adcomms (21)
Allergies (89)
Alliances (51435)
ALS (92)
Alzheimer's disease (1396)
Antibody-drug conjugate (ADC) (132)
Approvals (16580)
Artificial intelligence (266)
Autoimmune disease (23)
Automation (16)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (111)
Biotechnology (188)
Bladder cancer (77)
Brain cancer (29)
Breast cancer (281)
Cancer (2286)
Cardiovascular disease (182)
Career advice (1751)
Career pathing (31)
CAR-T (152)
Cell therapy (427)
Cervical cancer (19)
Clinical research (67520)
Collaboration (855)
Compensation (530)
Complete response letters (25)
COVID-19 (2660)
CRISPR (45)
C-suite (247)
Cystic fibrosis (103)
Data (2207)
Decentralized trials (2)
Denatured (28)
Depression (45)
Diabetes (272)
Diagnostics (6452)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (111)
Drug shortages (28)
Duchenne muscular dystrophy (94)
Earnings (88259)
Editorial (38)
Employer branding (21)
Employer resources (149)
Events (115216)
Executive appointments (733)
FDA (17837)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (757)
Gene editing (110)
Generative AI (21)
Gene therapy (316)
GLP-1 (745)
Government (4537)
Grass and pollen (5)
Guidances (55)
Healthcare (18998)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (124)
Indications (30)
Infectious disease (2803)
Inflammatory bowel disease (140)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (98)
Interviews (322)
IPO (16785)
IRA (47)
Job creations (4057)
Job search strategy (1492)
Kidney cancer (10)
Labor market (38)
Layoffs (488)
Leadership (17)
Legal (8379)
Liver cancer (76)
Lung cancer (322)
Lymphoma (155)
Machine learning (7)
Management (59)
Manufacturing (317)
MASH (68)
Medical device (13459)
Medtech (13464)
Mergers & acquisitions (20383)
Metabolic disorders (702)
Multiple sclerosis (79)
NASH (17)
Neurodegenerative disease (93)
Neuropsychiatric disorders (29)
Neuroscience (1949)
NextGen: Class of 2025 (6637)
Non-profit (4528)
Northern California (2674)
Now hiring (39)
Obesity (376)
Opinion (229)
Ovarian cancer (76)
Pain (94)
Pancreatic cancer (84)
Parkinson's disease (150)
Partnered (21)
Patents (237)
Patient recruitment (109)
Peanut (49)
People (59269)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20941)
Phase II (29705)
Phase III (22265)
Pipeline (1191)
Policy (150)
Postmarket research (2654)
Preclinical (8921)
Press Release (68)
Prostate cancer (107)
Psychedelics (31)
Radiopharmaceuticals (252)
Rare diseases (396)
Real estate (6258)
Recruiting (67)
Regulatory (23133)
Reports (46)
Research institute (2369)
Resumes & cover letters (358)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (76)
Series A (132)
Series B (85)
Service/supplier (12)
Sickle cell disease (55)
Southern California (2297)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3725)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (41)
The Weekly (49)
United States (23171)
Vaccines (704)
Venture capitalists (41)
Weight loss (250)
Women's health (35)
Worklife (15)
Date
Today (199)
Last 7 days (887)
Last 30 days (2759)
Last 365 days (33403)
2025 (10657)
2024 (35771)
2023 (40631)
2022 (51801)
2021 (56330)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32662)
2015 (38616)
2014 (32516)
2013 (27631)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Alabama (53)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (40720)
Australia (6522)
California (6113)
Canada (2016)
China (536)
Colorado (268)
Connecticut (273)
Delaware (149)
Europe (86931)
Florida (907)
Georgia (204)
Idaho (57)
Illinois (542)
India (26)
Indiana (315)
Iowa (11)
Japan (163)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (894)
Massachusetts (4596)
Michigan (218)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1729)
New Mexico (29)
New York (1738)
North Carolina (981)
North Dakota (8)
Northern California (2674)
Ohio (202)
Oklahoma (14)
Oregon (39)
Pennsylvania (1379)
Puerto Rico (12)
Rhode Island (33)
South America (1162)
South Carolina (22)
South Dakota (1)
Southern California (2297)
Tennessee (101)
Texas (909)
Utah (182)
Virginia (152)
Washington D.C. (61)
Washington State (558)
West Virginia (3)
Wisconsin (56)
718,327 Results for "actinium pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies
April 8, 2025
·
4 min read
Press Releases
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
April 24, 2025
·
4 min read
Press Releases
Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma
April 29, 2025
·
6 min read
Pharm Country
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
Actinium Pharmaceuticals, Inc. announced that it has launched a strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 leveraging its propriety cyclotron-based method.
March 11, 2024
·
6 min read
Cancer
Actinium to Farm Out AML Radioactive Drug After FDA Asks for Another Trial
The FDA is looking for stronger overall survival data to back Actinium’s application for Iomab-B, an investigational therapy that will allow acute myeloid leukemia patients to receive bone marrow transplants.
August 6, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
Actinium Pharmaceuticals, Inc. today announced it will host a KOL webinar on Monday, May 20, 2024, at 8:00 AM ET.
May 15, 2024
·
6 min read
Drug Development
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Actinium Pharmaceuticals, Inc. announced that an abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium’s ARC Actimab-A in acute myeloid leukemia models was presented at the 2024 European Hematology Association Congress held June 13 – 16, 2024, in Madrid, Spain.
June 17, 2024
·
5 min read
Drug Development
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) today highlighted data from the completed Phase 1b combination trial of Actimab-A + CLAG-M in patients with relapsed or refractory acute myeloid leukemia (r/r AML) at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting held June 8 – 11, 2024, in Toronto, Canada.
June 11, 2024
·
5 min read
Drug Development
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain.
June 14, 2024
·
5 min read
Pharm Country
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe, taking place November 6 – 8, 2023 in Munich, Germany.
November 2, 2023
·
2 min read
1 of 71,833
Next
